

Format for ANSWERING REVIEWERS

July 14, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: **1683**-review.doc).

Title: Clinical Trials on Corticosteroids for Diabetic Macular Edema

Author: Hassan A. Al Dhibi, MD, J. Fernando Arevalo, MD FACS

Name of Journal: *World Journal of Diabetes*

ESPS Manuscript NO: **1683**

I would like to thank you for your valuable comments

1-The title is reworded and changed to 'Clinical Trials on Corticosteroids for Diabetic Macular Edema'

2- The summary has been expanded . (page11)

3- Some discussion and modification of the statement have been added to various sections to explain why should be steroid considered as an essential effective adjunct modality in the treatment of refractory DME. Indeed we use it particularly for refractory DME which is not responding to conventional laser or anti-VEGF, i.e. not as first line of treatment. So, we modified as :

"Despite clearly identified side effects of increased IOP and cataracts with ocular use of corticosteroid, we still consider that corticosteroid is one of the useful effective adjunct modalities in the treatment of refractory DME with the advantage of repeatability, and based on short and intermediate term outcome of visual acuity and macular thickness improvement." These effects were modified , mentioned and discussed in most of the sections.

4- Terminology and abbreviation have been reviewed and corrected.

5- IOP in peribulbar section has been modified to include the rate of IOP elevation in steroid responder.(Page 6)

6- More details about IOP elevation in Ozurdex groups were added. (Page 8)

Thank you again for publishing our manuscript in the *World Journal of Diabetes*.

Sincerely yours,

Hassan A. Al Dhibi, MD

Vitreoretinal Division

The King Khaled Eye Specialist Hospital

Al-Oruba Street, PO Box 7191

Riyadh 11462, Kingdom of Saudi Arabia

Phone: +966 (1) 482-1234

Fax: +966 (1) 482-1234 xt. 3727

E-mail address:

hdhibi@kkesh.med.sa

hdhibi@yahoo.com